Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Journal: Gynecologic oncology
Published: March 17, 2024
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 11, 2020
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 28, 2018
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 30, 2016
Showing 1-5 of 5
Last Updated: 09/26/2026